Glucose Health, Inc. (GLUC) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · OTC
Glucose Health, Inc. (GLUC) stock forecast summary
Our AI scores Glucose Health, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Glucose Health, Inc. is a small-cap company with a market capitalization of $9M. It ranks number 20 by market capitalization among the 28 Medicinal Chemicals & Botanical Products issuers in our coverage with a current forecast.
For GLUC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 19.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, GLUC included.
GLUC price chart and AI forecast
How GLUC ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Glucose Health, Inc. (GLUC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Medicinal Chemicals & Botanical Products peers listed below that report each metric.
Valuation & Market
| Metric | GLUC | Rank |
|---|---|---|
| Market Cap | $9M | 20/28 |
Financial Health
| Metric | GLUC | Rank |
|---|---|---|
| Interest Coverage | 0.8x | 8/21 |
Cash Flow
| Metric | GLUC | Rank |
|---|---|---|
| Operating Cash Flow | -$20K | 12/27 |
Income Statement
| Metric | GLUC | Rank |
|---|---|---|
| Operating Income | -$40K | 7/26 |
| Cost of Goods Sold | $30K | 20/22 |
Dividend & Shareholder Information
| Metric | GLUC | Rank |
|---|---|---|
| Shares Outstanding | 27M | – |
Balance Sheet Highlights (USD millions)
| Total Liabilities | $450K |
GLUC quarterly financials and insider trading
Glucose Health, Inc. (GLUC) industry peers
Companies classified under the same SEC industry code as Glucose Health, Inc. (Medicinal Chemicals & Botanical Products): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| GLUC Glucose Health, Inc. | $9M | |
| DFTX Definium Therapeutics, Inc. | $4.47B | |
| TRLV Trulieve Cannabis Corp. | $1.97B | |
| CRON Cronos Group Inc. | $1.33B | |
| TLRY Tilray Brands, Inc. | $432M | |
| SNDL Sndl Inc. | $355M | |
| ACB Aurora Cannabis Inc | $332M | |
| CGC Canopy Growth Corp | $276M | |
| USNA Usana Health Sciences Inc | $256M | |
| GLAS Glass House Brands Inc. | $196M | |
| MDWD Mediwound Ltd. | $171M | |
| NAGE Niagen Bioscience, Inc. | $164M | |
| AAWH Ascend Wellness Holdings, Inc. | $75M | |
| FTLF Fitlife Brands, Inc. | $75M | |
| CHUC Charlie's Holdings, Inc. | $31M | |
| BTMD Biote Corp. | $30M | |
| MRMD Marimed Inc. | $26M | |
| HYEX Healthy Extracts Inc. | $21M | |
| MTEX Mannatech Inc | $16M | |
| ADIA Adia Med, Inc. | $9M | |
| BON Bon Natural Life Ltd | $7M | |
| NAII Natural Alternatives International Inc | $7M | |
| PLSH Panacea Life Sciences Holdings, Inc. | $6M | |
| AIBT Aibotics, Inc. | $3M | |
| CYAN Cyanotech Corp | $3M | |
| IMCC Im Cannabis Corp. | $980K | |
| NPHC Nutra Pharma Corp | $720K | |
| MEHA Functional Brands Inc. | $140K | |
| NTRR Neutra Corp. | N/A | |
| SNYRQ Synergy Chc Corp. | N/A |
Where GLUC sits on the market map
Glucose Health, Inc. (GLUC) stock news
Loading...
Glucose Health, Inc. (GLUC) stock forecast FAQ
What is the Glucose Health, Inc. (GLUC) stock forecast?
Our AI scores Glucose Health, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Glucose Health, Inc. stock predictions?
For GLUC, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 19.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 27.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Glucose Health, Inc. forecasts updated?
Glucose Health, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Glucose Health, Inc.'s industry peers?
30 issuers in our coverage, GLUC included, share the SEC industry code Medicinal Chemicals & Botanical Products. The largest are: Definium Therapeutics, Inc. (DFTX), Trulieve Cannabis Corp. (TRLV), Cronos Group Inc. (CRON), Tilray Brands, Inc. (TLRY), Sndl Inc. (SNDL), Aurora Cannabis Inc (ACB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.